CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network

Y. Saito, L. K. Stamp, K. E. Caudle, M. S. Hershfield, E. M. McDonagh, J. T. Callaghan, W. Tassaneeyakul, T. Mushiroda, N. Kamatani, B. R. Goldspiel, E. J. Phillips, T. E. Klein, M. T.M. Lee

Research output: Contribution to journalReview article

60 Scopus citations

Abstract

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B 58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

Original languageEnglish (US)
Pages (from-to)36-37
Number of pages2
JournalClinical Pharmacology and Therapeutics
Volume99
Issue number1
DOIs
StatePublished - Jan 1 2016

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network'. Together they form a unique fingerprint.

  • Cite this

    Saito, Y., Stamp, L. K., Caudle, K. E., Hershfield, M. S., McDonagh, E. M., Callaghan, J. T., Tassaneeyakul, W., Mushiroda, T., Kamatani, N., Goldspiel, B. R., Phillips, E. J., Klein, T. E., & Lee, M. T. M. (2016). CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clinical Pharmacology and Therapeutics, 99(1), 36-37. https://doi.org/10.1002/cpt.161